Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NTRBW) delivers innovative transdermal solutions addressing critical pharmaceutical safety challenges through its proprietary AVERSA® technology. This dedicated news hub provides investors and industry stakeholders with essential updates about regulatory progress, product development milestones, and strategic partnerships.
Access real-time announcements covering clinical trial developments, intellectual property expansions, manufacturing agreements, and consumer product launches. Our curated feed includes earnings reports, FDA submission updates, and analysis of technologies combating opioid misuse through abuse-deterrent systems.
Key focus areas include advancements in transdermal drug delivery systems, international patent grants, and collaborations with industry leaders like Kindeva Drug Delivery. Stay informed about Nutriband's progress in integrating Bitrex®-based safety mechanisms across therapeutic applications while maintaining compliance with global regulatory standards.
Bookmark this page for verified updates about Nutriband's mission to enhance medication safety through cutting-edge transdermal innovations. Monitor critical developments in pharmaceutical abuse prevention and topical delivery systems from a single authoritative source.
Nutriband (NASDAQ:NTRB) has declared a 25% preferred stock dividend, where shareholders will receive one preferred share for every four common shares held as of July 25th, 2025, with distribution set for August 5th. The preferred shares are convertible to common stock upon FDA approval of AVERSA Fentanyl product.
These preferred shares will be eligible for annual cash dividends from company profits if not converted. CEO Gareth Sheridan emphasized the company's focus on shareholder value creation and highlighted recent progress with Kindeva on commercialization manufacturing as they prepare for FDA approval submission.
Nutriband Inc. (NASDAQ:NTRB) has achieved a significant milestone with its inclusion in four Russell indexes: the Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index, and Russell 3000E Growth Index as part of the 2025 Russell indexes reconstitution.
CEO Gareth Sheridan highlighted the company's AVERSA pipeline development, particularly AVERSA Fentanyl, which has a projected peak annual US sales potential of $80 million to $200 million. The company aims to enhance the safety profile of easily abused medications while ensuring availability to patients in need.
The Russell indexes, which serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. FTSE Russell will transition to a semi-annual reconstitution frequency starting in 2026.
Nutriband CEO Gareth Sheridan released a shareholder letter highlighting the company's achievements in 2024 and outlook for 2025. The company is developing AVERSA technology, aimed at creating the world's first abuse-deterrent transdermal drug delivery system.
In partnership with Kindeva Drug Delivery, Nutriband is developing AVERSA Fentanyl, projected to reach peak annual sales of $80M-$200M. Their second product, AVERSA Buprenorphine, is estimated to achieve $70M-$130M in peak annual sales. The company secured $8.4M through private placement in April 2024 and expanded its patent portfolio to 46 countries.
Key 2025 objectives include:
- Conducting Human Abuse Liability clinical trials for AVERSA Fentanyl
- Filing an Investigational New Drug application with FDA
- Exploring international partnerships
- Growing revenue through Pocono Pharma subsidiary's kinesiology tape manufacturing
Nutriband Inc. (NASDAQ:NTRB) has secured a patent in Macao for its AVERSA abuse deterrent transdermal technology. The patent, J/9010, was granted on February 11, 2025, protecting the company's 'Abuse and Misuse Deterrent Transdermal Systems.'
AVERSA technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs with high abuse potential, such as opioids and stimulants.
The company is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the first abuse-deterrent opioid patch globally. The product aims to deter abuse and reduce accidental exposure risks, with projected peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB) has announced signing an Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which they position as potentially becoming the world's first abuse deterrent patch platform for chronic pain management.
Nutriband Inc. (NASDAQ:NTRB) has announced a new Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which is being developed as a potential first-of-its-kind abuse deterrent patch platform for chronic pain management.
FAQ
What is the current stock price of Nutriband (NTRBW)?
